This study further supports our chosen strategy to limit the therapeutic window for S100A8/A9 blockade to the acute inflammatory phase post-MI, and provide important supporting information for the beneficial cardioprotective effects of the treatment. This evidence concerns the gene S100A8 and myocardial infarction.